Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after 177Lu[Lu]-octreotate therapy-Reference-Cited by-同舟云学术

Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after 177Lu[Lu]-octreotate therapy

Published:2018-05 Issue: Volume:60 Page:11-18
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Spetz Johan^ORCID,Rudqvist Nils,Langen Britta,Parris Toshima Z.,Dalmo Johanna,Schüler Emil,Wängberg Bo,Nilsson Ola,Helou Khalil^ORCID,Forssell-Aronsson Eva^ORCID

Funder

Swedish Research Council

Swedish Cancer Society

BioCARE

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Molecular Medicine

Reference41 articles.

1. Phase 3 trial of 177Lu-dotatate for Midgut neuroendocrine tumors;Strosberg;N Engl J Med,2017

2. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience;Delpassand;Pancreas,2014

3. [177Lu-DOTA0-Tyr3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney;Sward;World J Surg,2010

4. Radionuclide therapy via SSTR: future aspects from experimental animal studies;Forssell-Aronsson;Neuroendocrinology,2013

5. Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour;Kölby;Br J Cancer,2005

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model;Therapeutics;2024-08-07

2. Gene Abnormalities and Modulated Gene Expression Associated with Radionuclide Treatment: Towards Predictive Biomarkers of Response;Genes;2024-05-26

3. Comparison of 177Lu-octreotate and 177Lu-octreotide for treatment in human neuroblastoma-bearing mice;Heliyon;2024-05

4. Co-administration with A1M does not influence apoptotic response of 177Lu-octreotate in GOT1 neuroendocrine tumors;Scientific Reports;2023-04-19

5. Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy;International Journal of Molecular Sciences;2022-10-15